DPP-4i do not increase weight and SGLT2i are expected to reduce weight; thus, are widely used in daily practice. SGLT2i are recommended as second-line drugs after metformin (Met) in those at high risk of atherosclerotic cardiovascular disease (ASCVD), but suitable second-line drugs for the majority of patients not at high risk are not yet determined. Furthermore, reports of appropriate second-line drugs in East Asians who have a lower risk of ASCVD than Europeans are scarce. We compared the effects of ipraglifrozin (Ipra) and sitagliptin (Sita) after Japanese patients with type 2 diabetes had been taking Met and were without prior ASCVD in a 52-week randomized open-label trial (jRCTs031180205). The primary endpoint (PE) was a HbA1c reduction of ≥0.5% with no weight gain at 52 weeks. Among 111 patients (mean age 59.2 y, mean BMI 26.6 kg/m2, and male 61.3%), 54 and 57 patients received Ipra and Sita, respectively. After 52 weeks, achievement of the PE was statistically the same (37.0% and 40.3%, p=0.72), as was the HbA1c reduction ≥0.5% (38.9% and 54.4%, p=0.13). Lack of weight gain was higher for Ipra than Sita (94.4% and 54.4%, p<0.01). BMI, C-peptide and HDL-C improved with Ipra vs. Sita (p<0.05). Withdrawal for any adverse event occurred in 8 with Ipra and 4 with Sita (14.8% and 7.0%, p=0.23).Although glycemic control did not differ between Ipra and Sita, some ASCVD risk factors improved with Ipra.


M. Kitazawa: None. T. Katagiri: None. H. Suzuki: None. S. Matsunaga: None. M.H. Yamada: None. T. Ikarashi: None. M. Yamamoto: None. K. Furukawa: None. M. Iwanaga: None. M. Hatta: None. K. Fujihara: None. T. Yamada: None. S. Tanaka: None. H. Sone: Research Support; Self; Kyowa Hakko Kirin Co., Ltd., Novartis AG, Ono Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co.


Astellas Pharma Inc.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.